Definitive treatment of Graves' disease in children and adolescents

Endokrynol Pol. 2021;72(6):661-665. doi: 10.5603/EP.a2021.0092. Epub 2021 Dec 2.

Abstract

Graves' disease (GD) is the most common cause of paediatric hyperthyroidism. In children and adolescents, the clinical GD course is different from that seen in adults, due to low remission rate and high prevalence of adverse events related to treatment with antithyroid drugs (ATDs). Most patients in this group require definitive therapy. As in adults, there are 2 treatment options- thyroid ablation with radioactive iodine (RAI) or surgery with preferred procedure of total thyroidectomy (TT). The choice of definitive therapy depends on many important factors such as the child's age, effectiveness of the first-line ATD treatment, presence of ATD side effects, presence of large goitre or thyroid nodules, and concomitant diseases. The following paper provides the current guidelines on GD management in children and compares the efficacy of both definitive treatment methods as well as the acute and long-term complication rates, which must be taken into account when choosing the optimal therapeutic option.

Keywords: Graves’ disease (GD); antithyroid drugs (ATDs); radioactive iodine (RAI); total thyroidectomy (TT).

MeSH terms

  • Adolescent
  • Antithyroid Agents / adverse effects
  • Antithyroid Agents / therapeutic use*
  • Child
  • Graves Disease / drug therapy
  • Graves Disease / therapy*
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Thyroid Neoplasms
  • Thyroidectomy*
  • Treatment Outcome

Substances

  • Antithyroid Agents
  • Iodine Radioisotopes